Androgen Receptor Antagonists

01/01/2019 - "This review covers a survey of most promising classes of non-steroidal androgen receptor antagonists, also providing insights into their mechanism of action and efficacy in treating prostate cancer."
09/01/2020 - "Second-generation androgen receptor antagonists have demonstrated efficacy in earlier disease settings, fulfilling an unmet need in the treatment of patients with advanced prostate cancer. "
11/01/2023 - "Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists."
02/21/2023 - "Cheminformatic Analysis and Machine Learning Modeling to Investigate Androgen Receptor Antagonists to Combat Prostate Cancer."
02/11/2023 - "DIM was the first pure androgen receptor antagonist isolated from the Brassicaceae family and has been recently investigated for its potential pharmacological use in prostate cancer prevention and treatment. "

02/22/2021 - "Additionally, we have reported that men taking antiandrogenic drugs, e.g., 5-alpha-reductase inhibitors (5ARis), are less likely to have severe COVID-19. Here we aimed to test whether the androgen receptor antagonist, Proxalutamide, would be a beneficial treatment for subjects with SARS-CoV-2 infection. "
01/01/2021 - "The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. "
01/01/2023 - "Proxalutamide as an androgen receptor antagonist has shown potential treatment effects on COVID-19 patients. "
01/01/2022 - "Enzalutamide, an oral androgen receptor antagonist, had no impact on SARS-CoV-2 infection. "
01/01/2020 - "Interventional approaches including estrogen-related compounds and androgen receptor antagonists may be considered in patients with COVID-19."

11/13/2008 - "4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. "
04/01/2021 - "Compound 16 (olean-12-en-3beta-ol, cinnamate) is therefore a potential androgen receptor antagonist and may be beneficial in the treatment of alopecia."
01/01/2022 - "Therefore, bufotalinin, a steroid compound, is a potential androgen receptor antagonist and could be useful in the treatment of alopecia."
05/01/2011 - "Treatment of female pattern hair loss with the androgen receptor antagonist flutamide."
04/01/2003 - "Also, after the topical treatment with TOS extract and androgen receptor antagonist (cyproterone acetate) simultaneously with subcutaneous injection of testosterone (1 mg/mice/day), hair loss patterns of female B6CBAF1/j hybrid mouse were observed. "

01/01/2020 - "In our search for novel androgen receptor antagonists, we focus on the Traditional Chinese Medicine (TCM), which has been used for thousands of years to prove effective in the treatment of cancer. "
07/01/2017 - "Different non-steroidal androgen receptor antagonists are approved also in the case of castration-resistant cancer forms. "
11/01/2013 - "Although initially effective, resistance to these androgen receptor antagonists usually develops and the cancer quickly progresses to castration-resistant and metastatic states. "
01/01/2017 - "Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse."
04/06/2016 - "Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse."

04/02/2013 - "Spironolactone, a mineralocorticoid and androgen receptor antagonist, has been shown to improve endothelial function and reduce inflammation. "
12/01/2003 - "In fact, it appears that endogenous testosterone inhibits wound healing and promotes inflammation since castration of male mice or systemic treatment with the androgen receptor antagonist flutamide accelerates cutaneous wound healing and reduces the inflammatory response. "